New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities On Friday, Quantum Foundry Copenhagen and the Novo Nordisk Foundation announced plans to establish a new 5,300 m² quantum chip fabrication facility in Copenhagen. The facility will develop and scale the advanced manufacturing equipment needed to produce the next generation of quantum chips and strengthen Europe’s […]
ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]
Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]
